IOVA Iovance Biotherapeutics, Inc. Common Stock
XNAS
14.21
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
IOVA
$14.21
—
Key stats
$14.21
Pre-market
$14.10
-0.77%
- 52-Week Range
- $1.76 – $15.30
- YTD
- +463.89%
- IV Rank (30D)
- 18.78
- Straddle Price
- $3.47
- P/C Vol Ratio
- 0.67
- Market Cap
- $6.2B
- Open
- $13.80
- Day Range
- $13.78 – $14.74
- Volume
- 8,503,802
- Prev Close
- $13.62
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.10% |
| Beta vs SPY | 1.17 |
| Cost of Equity (CAPM) | 11.55% (VRP-adj) |
| WACC | 11.59% |
| Volatility Risk Premium | +20.8pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +30.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.3B |
| Return on Equity (TTM) | -39.3% |
| Book / Price | 13.0% |
| Gross Margin (TTM) | 48.4% |
| FCF Margin (TTM) | -91.2% |
| Debt / Equity | 0.00 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $10.28 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $13.26 |
| Bollinger Width / SMA20 | 354.3% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $6B |
Peers used for multiples: GMAB, IBRX, MRK, MRNA, REGN, RVMD, TWST, VRTX
60-Day Conviction
86%
20-Day Fair Value
≈ by Nov 18, 2026
$14.53
α +2.3%
rank 76%
conviction
93%
40-Day Fair Value
≈ by Dec 17, 2026
$14.61
α +2.8%
rank 62%
conviction
80%
60-Day Fair Value
≈ by Jan 15, 2027
$14.68
α +3.3%
rank 68%
conviction
86%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 28.8× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 23.5× · 3 peers |
| Peer P/B | $19.87 | 11% | median 10.7× · 6 peers |
| Peer P/S | $13.69 | 11% | median 15.2× · 6 peers |
| Market Anchor (SMA50) | $10.28 | 49% | stability 85% (BB-width) |
| Options Expected (B-L 30d) | $13.66 | 29% | 29 strikes · skew +0.24 |
As of 2026-10-20 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $6.2B
- Employees
- 975
- List Date
- 2010-05-26
- CIK
- 0001425205
- Next Earnings
- 2026-11-05 (After-Close)
- EPS Forecast
- ($0.09) (3 est.)
- Headquarters
- San Carlos, CA
- Homepage
- https://www.iovance.com
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor can…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -5.23% | -12.83% | 30.28% | -4.57% | -24.90% | 1.19% | -2.68% |
| Feb | -15.27% | -7.66% | -7.84% | 97.39% | -24.91% | 47.89% | 14.93% |
| Mar | -19.79% | 7.91% | -16.30% | -11.73% | -17.57% | -7.39% | -10.81% |
| Apr | -2.42% | -11.46% | -10.19% | -16.98% | 10.46% | -2.61% | -5.53% |
| May | -41.53% | -58.82% | 35.93% | -28.96% | -47.45% | 20.59% | -20.04% |
| Jun | 42.42% | 73.04% | -19.36% | -4.18% | -2.27% | 5.05% | 15.78% |
| Jul | -16.22% | 1.57% | 2.25% | 8.31% | 47.70% | 2.78% | 7.73% |
| Aug | 7.03% | -3.60% | -15.99% | 42.89% | -16.79% | 89.34% | 17.15% |
| Sep | 1.44% | -12.43% | -26.02% | -13.46% | -0.91% | 78.99% | 4.60% |
| Oct | -7.74% | 0.00% | -13.77% | 11.66% | -10.86% | -0.14%* | -3.47% |
| Nov | -24.52% | -31.70% | 56.85% | -16.71% | 26.67% | -- | 2.12% |
| Dec | 8.59% | -0.31% | 29.87% | -18.41% | 22.42% | -- | 8.43% |
| Total | -64.00% | -68.01% | 10.43% | -4.51% | -55.61% | 494.74% | 52.18% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $13.26
SMA 50: $10.28
SMA 200: $5.35
Current: $14.21
EMA 12: $13.80
EMA 26: $12.56
MACD: 1.2424 | Signal: -0.1340
BULLISH
ADX (14): 52.84
STRONG TREND
+DI: 29.03
−DI: 14.79
Momentum Oscillators
RSI (14): 63.21
NEUTRAL
Stoch %K: 66.37
Stoch %D: 72.79
Williams %R: -32.14
Volume & Volatility
BB Upper: $16.37
BB Lower: $10.14
NEUTRAL
OBV: 109,230,902
Vol SMA 20: 17,256,232
Vol ROC: -27.72%
ATR: $0.89
True Range: $1.12
HV 20: 118.6%
HV 30: 101.5%
HV 60: 116.4%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-21T00:00:00 – 2026-10-19T00:00:00
AI Analysis
IOVA Stock Analysis Report
Iovance Biotherapeutics Inc. | Analysis Date: October 9, 2026
Executive Summary
Overall Assessment: BULLISH | Confidence Level: 7/10
Iovance Biotherapeutics (IOVA) presents a compelling bullish case driven by strong momentum and positive fundamental catalysts, though elevated technical readings warrant caution on entry timing. The stock has surged 31.5% on September 30th following raised 2026 revenue guidance and a Chief Medical Officer appointment, establishing a new 52-week high. Technical indicators show strong trend confirmation with an ADX of 56.11 (strong trend regime) and MACD in bullish alignment, but RSI at 70.61 signals overbought conditions that could trigger a near-term pullback before further appreciation.
Investment Thesis: IOVA is positioned at an inflection point in its development cycle with improved guidance, executive leadership strengthening, and clear technical momentum. The positive news sentiment aligns with technical strength, supporting a medium-term bullish thesis, though near-term volatility and profit-taking risk exist given the recent 31.5% rally.
Recent News Sentiment Impact: All six recent headlines carry positive sentiment, with the September 30th announcements (raised revenue outlook and 31.5% surge) serving as the primary catalyst for the current price action. The October 1st CMO appointment reinforces institutional confidence, while October 2nd and 9th coverage emphasize the stock's earnings upside potential—suggesting the market is positioning ahead of the November 5th earnings release.
Technical Analysis
Trend Direction
| Timeframe | Status | Rationale | |-----------|--------|-----------| | Short-term (1-4 weeks) | STRONG UPTREND | Price at $14.62 trades well above SMA 20 ($12.88), SMA 50 ($9.97), and SMA 200 ($5.24). EMA 12 ($13.73) > EMA 26 ($12.33) confirms upward momentum. ADX 56.11 signals a strong directional trend. | | Medium-term (1-3 months) | STRONG UPTREND | All moving averages in bullish alignment (20 > 50 > 200). Price has moved 179% from the 200-day average ($5.24), indicating sustained appreciation. | | Long-term (3-12 months) | EMERGING UPTREND | The 200-day SMA at $5.24 vs current price $14.62 shows a 179% advance, though long-term trend is still establishing. Prior resistance/support structure unclear from available data. |
Support & Resistance Levels
| Level | Price | Significance | |-------|-------|--------------| | Immediate Resistance | $16.42 | Bollinger Bands upper band; represents first technical ceiling. Options market pricing $3.78 expected move suggests potential target near $18.40 (current + expected move). | | Secondary Resistance | $18.40 | Implied by 29-DTE expected move; psychological level for new highs. | | Primary Support | $12.88 | SMA 20; zone of strong support if pullback occurs. Loss of this level would signal momentum loss. | | Secondary Support | $9.97 | SMA 50; critical support zone. Break below would suggest trend reversal to medium-term downtrend. | | Tertiary Support | $9.34 | Bollinger Bands lower band; represents capitulation level. |
Momentum Signals
RSI (14): 70.61 — OVERBOUGHT WARNING
- Reading above 70 indicates overbought conditions, historically associated with pullback risk or consolidation
- However, strong uptrends can sustain elevated RSI; this is not a sell signal in isolation
- A reading above 80 would suggest more pronounced mean reversion risk
- Interpretation: Monitor for RSI divergence (price higher but RSI lower) as a potential reversal signal
Stochastic Oscillator: %K 82.09 / %D 83.35 — EXTREME OVERBOUGHT
- Both %K and %D above 80 indicate extremely overbought conditions
- This oscillator is more sensitive than RSI and suggests shorter-term pullback is more likely
- Historically, Stochastic >80 precedes 3-5 day consolidation or 2-4% pullback before resumption of uptrend
- Interpretation: High probability of near-term profit-taking; support test likely within 1-2 weeks
Williams %R: -14.61 — OVERSOLD within indicator scale (note: inverted)
- Indicates strong buying pressure at current levels (closer to 0 than -100)
- Interpretation: Confirms sustained demand; bullish signal
MACD: 1.41 (MACD Line) / -0.03 (Signal) / 1.44 (Histogram) — STRONG BULLISH
- MACD line (1.41) well above signal line (-0.03) with positive histogram (1.44)
- MACD recently crossed above signal line, confirming upward momentum initiation
- Magnitude of histogram (1.44) suggests strong momentum strength
- Interpretation: Bullish momentum confirmed; no divergence warning signs yet
Bollinger Bands: Width 55.01 — NEUTRAL/EXPANDING
- Band width of 55.01 (measured as % of middle band) suggests moderate volatility expansion
- Price positioned in upper third of bands but not touching upper band ($16.42)
- Middle band ($12.88) = SMA 20, providing dynamic support
- Interpretation: Volatility is expanding but not extreme; room to move within bands before mean reversion
Volume Analysis
| Metric | Value | Interpretation | |--------|-------|-----------------| | Volume SMA 20 | 17.84M shares | Average daily volume baseline | | Volume Rate of Change | -50.68% | Current volume is ~50% below the 20-day average—significant weakness | | On-Balance Volume (OBV) | 116.33M | Strong cumulative buying pressure; OBV in uptrend | | Institutional Signal | MIXED | OBV strength suggests institutional accumulation, but declining volume rates suggest retail capitulation or consolidation phase |
Critical Observation: The -50.68% volume decline is concerning for trend sustainability. The recent 31.5% rally on September 30th likely occurred on elevated volume, but current volume trailing suggests consolidation rather than continued strong accumulation. This is a yellow flag—strong uptrends should show volume confirmation on new highs.
News & Sentiment Analysis
Recent Headlines Summary
Positive Catalyst Cluster (September 30 - October 9):
-
September 30 - Raised Revenue Outlook + 31.5% Surge (Most Significant)
- Company raised 2026 revenue guidance, triggering immediate 31.5% rally
- This is a fundamental catalyst directly supporting technical strength
- Timing aligns perfectly with technical breakout
-
October 1 - Chief Medical Officer Appointment
- Appointment of Noah Berkowitz, M.D., Ph.D. as CMO signals strengthened clinical/regulatory leadership
- Typically positive for biotech stocks (de-risks clinical development execution)
- Reinforces institutional confidence in management bench strength
-
October 2 & 9 - Earnings Beat Positioning
- Zacks coverage highlighting IOVA as one of two medical stocks "set to beat earnings"
- Suggests analyst consensus building toward positive earnings surprise
- October 9th headline from same source indicates sustained analyst bullishness
-
October 21 - Biotech Sector Tailwind
- Reference to "cancer drug breakthroughs accelerate" positions IOVA within favorable sector narrative
- Broader biotech momentum could provide secondary support to stock
Sentiment Assessment
Aggregate Sentiment: STRONGLY POSITIVE (6/6 headlines positive)
- No negative headlines present in recent coverage
- Absence of regulatory/clinical/legal concerns in available news
- Analyst coverage from Zacks Investment Research (reputable source) reinforcing bullish case
- Thematic alignment: News narrative matches technical breakout timing
Potential Bias: All news sources appear to be from investment research/financial media. No independent news outlets (Reuters, Bloomberg, AP) in this sample. News may reflect retail-focused sentiment rather than institutional consensus.
Catalyst Identification
|
Generated
News
All IOVA news →
An influential investment bank resumed its coverage of the company.
Earnings History
20 of 23 under expected move
Avg Expected Move
20.01%
Avg Actual Move
9.40%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-25 | After-Close | 15.67% | 2.16% | 0.14x | Within |
| 2021-05-06 | After-Close | 21.50% | 0.31% | 0.01x | Within |
| 2021-08-05 | After-Close | 14.75% | 1.63% | 0.11x | Within |
| 2021-11-04 | After-Close | 18.44% | 2.00% | 0.11x | Within |
| 2022-02-24 | After-Close | 16.84% | 4.71% | 0.28x | Within |
| 2022-05-05 | After-Close | 17.53% | 2.49% | 0.14x | Within |
| 2022-08-04 | After-Close | 15.95% | 2.87% | 0.18x | Within |
| 2022-11-03 | After-Close | 7.39% | 4.34% | 0.59x | Within |
| 2023-02-28 | After-Close | 18.11% | 0.14% | 0.01x | Within |
| 2023-05-09 | After-Close | 15.35% | 3.80% | 0.25x | Within |
| 2023-07-10 | After-Close | 17.75% | 9.78% | 0.55x | Within |
| 2023-11-07 | After-Close | 15.05% | 3.47% | 0.23x | Within |
| 2024-02-20 | After-Close | 10.22% | 31.09% | 3.04x | Exceeded |
| 2024-05-09 | After-Close | 15.76% | 18.48% | 1.17x | Exceeded |
| 2024-08-08 | After-Close | 42.19% | 24.94% | 0.59x | Within |
| 2024-11-07 | After-Close | 18.53% | 13.80% | 0.74x | Within |
| 2025-02-27 | After-Close | 54.18% | 19.49% | 0.36x | Within |
| 2025-05-08 | After-Close | 14.98% | 44.79% | 2.99x | Exceeded |
| 2025-08-07 | After-Close | 61.55% | 20.08% | 0.33x | Within |
| 2025-11-06 | After-Close | 16.23% | 0.43% | 0.03x | Within |
| 2026-02-24 | After-Close | 12.57% | 1.32% | 0.11x | Within |
| 2026-05-07 | After-Close | 8.45% | 1.97% | 0.23x | Within |
| 2026-08-06 | After-Close | 11.27% | 2.09% | 0.19x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
IOVA Options Activity & IV Rank
IOVA IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 111.7%
7-DTE IV: 127.7%
Expected Move: $3.47
7-DTE Move: $1.20
Days to Exp: 32 (2026-11-20)
Options Flow
Call Volume: 653
Put Volume: 435
P/C Volume: 0.666
BULLISH
Call OI: 10,234
Put OI: 4,192
P/C OI: 0.41
Total OI: 14,426
ATM Options Pricing
ATM Call: $1.82
ATM Put: $1.65
Call %: 12.8%
Put %: 11.6%
Chain Summary
Chain Volume: 18,532
Chain OI: 415,832
Last Updated: 10/19/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 93rd percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
93%
vs own history
GEX tilt
+0.54
OI-weighted, today
Vanna tilt
+0.55
δ-sensitivity to IV
Charm tilt
-0.64
δ-decay vs time
Vanna tilt +0.55: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.64: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 55 ATM contracts, 55k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 19 · ATM 96.2% / Wing —
30 DTE / 10d
95%
+17.6
pts
EXTREME
as of Oct 19 · ATM 104.4% / Wing 121.9%
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)23.8LowOct 19
IV Rank (30 DTE)18.8LowOct 19
Straddle Price (30 DTE)$3.47Oct 19
Beta Analysis
Risk Metrics
Beta: 1.2340
Alpha: 220.85%
Correlation: 0.1492
R-Squared: 2.2%
Stock Volatility: 105.3%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own IOVA
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $35.5M | #798 of 3716 | -9.4% | 13F | |
| Citadel Hedge fund Ken Griffin | $8.8M | #1687 of 6285 | -19.4% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $146K | #2769 of 4729 | -36.9% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
IOVA Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 397,520,500 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
12 filers$24.51M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $11.10M | 45.28% | 2026-06-30 |
| 2 | GROUP ONE TRADING LLC Custodian | $3.98M | 16.25% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $3.39M | 13.82% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $3.04M | 12.39% | 2026-06-30 |
| 5 | Simplex Trading, LLC Custodian | $1.33M | 5.42% | 2026-06-30 |
| 6 | Walleye Capital LLC | $923.10K | 3.77% | 2026-06-30 |
| 7 | Wolverine Trading, LLC Custodian | $470.08K | 1.92% | 2025-09-30 |
| 8 | TUDOR INVESTMENT CORP ET AL | $208.00K | 0.85% | 2026-06-30 |
| 9 | IMC-Chicago, LLC Custodian | $47.42K | 0.19% | 2026-06-30 |
| 10 | CWM, LLC Custodian | $14.50K | 0.06% | 2026-03-31 |
| 11 | Raiffeisen Bank International AG | $8.32K | 0.03% | 2026-06-30 |
| 12 | Walleye Trading LLC | $5.82K | 0.02% | 2026-06-30 |
8 filers$20.85M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $9.95M | 47.74% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $3.00M | 14.37% | 2026-06-30 |
| 3 | 683 Capital Management, LLC | $2.68M | 12.86% | 2026-06-30 |
| 4 | GROUP ONE TRADING LLC Custodian | $2.02M | 9.69% | 2026-06-30 |
| 5 | Simplex Trading, LLC Custodian | $1.54M | 7.37% | 2026-06-30 |
| 6 | Jane Street Group, LLC Custodian | $1.44M | 6.89% | 2026-06-30 |
| 7 | Walleye Capital LLC | $130.21K | 0.62% | 2026-06-30 |
| 8 | Wolverine Trading, LLC Custodian | $94.33K | 0.45% | 2025-09-30 |
IOVA Insider Trading (Form 4)
Latest: 2026-10-02Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Noah Berkowitz | Chief Medical Officer | Grant (A) | +450,000 RSU | — | EDGAR | |
| 2026-09-10 | Igor Bilinsky | Chief Operating Officer | Mixed | +3,837 | $8.70 | -$34.6K | EDGAR |
| 2026-09-10 | Frederick G Vogt | Interim CEO & General Counsel | Mixed | +8,988 | $8.70 | -$57.8K | EDGAR |
| 2026-09-10 | Raj K. Puri | Chief Regulatory Officer | Mixed | +5,288 | $8.70 | -$39.0K | EDGAR |
| 2026-09-03 | Raj K. Puri | Chief Regulatory Officer | Mixed | +2,962 | $8.28 | -$20.8K | EDGAR |
| 2026-09-03 | Igor Bilinsky | Chief Operating Officer | Mixed | +4,317 | $8.28 | -$37.0K | EDGAR |
| 2026-09-03 | Frederick G Vogt | Interim CEO & General Counsel | Mixed | +23,967 | $8.28 | -$146.6K | EDGAR |
| 2026-08-12 | Daniel Gordon Kirby | Chief Commercial Officer | Mixed | +7,565 | $6.40 | -$15.6K | EDGAR |
| 2026-08-10 | Corleen M. Roche | Chief Financial Officer | Mixed | +28,757 | $6.21 | -$131.9K | EDGAR |
| 2026-06-18 | Raj K. Puri | Chief Regulatory Officer | Grant (A) | +15,000 RSU | — | EDGAR | |
| 2026-06-18 | Ryan D Maynard | Director | Grant (A) | +90,316 RSU | — | EDGAR | |
| 2026-06-18 | Athena Countouriotis | Director | Grant (A) | +90,316 RSU | — | EDGAR | |
| 2026-06-18 | Iain D. Dukes | Director | Grant (A) | +180,632 RSU | — | EDGAR | |
| 2026-06-18 | Michael Weiser | Director | Grant (A) | +90,316 RSU | — | EDGAR | |
| 2026-06-09 | Finckenstein Friedrich Graf | Chief Medical Officer | Mixed | +3,837 | $4.23 | -$16.8K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
IOVA Insider Holdings
10 insiders · @ $14.21
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Frederick G Vogt | Interim CEO & General Counsel | 602,085 | $8.56M | $54.7K | 36 | 2026-09-10 |
| 2 | Raj K. Puri | Chief Regulatory Officer | 260,842 | $3.71M | $9.7K | 16 | 2026-09-10 |
| 3 | Daniel Gordon Kirby | Chief Commercial Officer | 154,511 | $2.20M | $55.2K | 7 | 2026-08-12 |
| 4 | Igor Bilinsky | Chief Operating Officer | 146,050 | $2.08M | $0 | 32 | 2026-09-10 |
| 5 | Michael Weiser | Director | 141,116 | $2.01M | $68.0K | 12 | 2026-06-18 |
| 6 | Finckenstein Friedrich Graf | Chief Medical Officer | 140,111 | $1.99M | $0 | 32 | 2026-06-09 |
| 7 | Jean-Marc Bellemin | Chief Financial Officer | 64,993 | $923.6K | $0 | 11 | 2025-06-04 |
| 8 | Iain D. Dukes | Director | 54,000 | $767.3K | $457.6K | 14 | 2026-06-18 |
| 9 | Corleen M. Roche | Chief Financial Officer | 49,995 | $710.4K | $0 | 3 | 2026-08-10 |
| 10 | Ryan D Maynard | Director | 7,500 | $106.6K | -$452.4K | 12 | 2026-06-18 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
IOVA Proposed Insider Sales (Form 144)
Latest: 2024-11-12
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2024-11-12 | Maynard Ryan D | Director | 50,000 | $503.1K | 2024-11-12 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
76 ETFs hold IOVA
25 shown · $980.04M total exposure · 0.21% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.01% | $200.8M | — | 2026-09-30 |
| 2 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 1.63% | $161.2M | $9.9B | 2026-10-16 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.19% | $139.3M | $74.8B | 2026-10-16 |
| 4 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.04% | $71.8M | — | 2026-09-30 |
| 5 | VXF Vanguard Extended Market ETF | Vanguard | 0.07% | $65.7M | — | 2026-09-30 |
| 6 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.37% | $50.2M | $13.5B | 2026-10-16 |
| 7 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.39% | $40.8M | $10.5B | 2026-10-16 |
| 8 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.19% | $34.3M | — | 2026-09-30 |
| 9 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.09% | $29.0M | — | 2026-10-16 |
| 10 | VBR Vanguard Morningstar Small-Cap Value ETF | Vanguard | 0.04% | $23.4M | — | 2026-09-30 |
| 11 | VBK Vanguard Morningstar Small-Cap Growth ETF | Vanguard | 0.05% | $20.0M | — | 2026-09-30 |
| 12 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.28% | $17.9M | $6.5B | 2026-10-16 |
| 13 | VHT Vanguard Health Care ETF | Vanguard | 0.08% | $17.2M | — | 2026-09-30 |
| 14 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.22% | $16.5M | — | 2026-10-16 |
| 15 | IDNA iShares Genomics Immunology and Healthcare ETF | iShares (BlackRock) | 4.80% | $14.8M | $311.0M | 2026-10-16 |
| 16 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.01% | $11.2M | — | 2026-10-16 |
| 17 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.31% | $9.6M | $3.1B | 2026-10-16 |
| 18 | FTXH First Trust Nasdaq Pharmaceuticals ETF | First Trust | 0.82% | $9.1M | $1.1B | 2026-10-16 |
| 19 | KOMP State Street® SPDR® S&P Kensho New Economies Composite ETF | SPDR (State Street) | 0.35% | $8.7M | $2.5B | 2026-10-16 |
| 20 | FYC First Trust Small Cap Growth AlphaDEX® Fund | First Trust | 0.61% | $7.9M | $1.3B | 2026-10-16 |
| 21 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.01% | $7.0M | $96.3B | 2026-10-16 |
| 22 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.03% | $6.6M | — | 2026-05-31 |
| 23 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 1.19% | $6.3M | — | 2026-10-19 |
| 24 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.40% | $5.4M | — | 2026-09-30 |
| 25 | VFMO Vanguard U.S. Momentum Factor ETF | Vanguard | 0.29% | $5.4M | — | 2026-10-16 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.70
TTM Revenue
$324.97M
TTM Net Income
$-289.52M
TTM Op. Cash Flow
$-264.18M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $99.31M | $-47.31M | $-0.11 | $-60.84M |
| Q1 '26 | 2026-03-31 | $71.43M | $-79.05M | $-0.19 | $-72.07M |
| Q4 '25 | 2025-12-31 | $86.77M | $-71.90M | $-0.15 | $-52.56M |
| Q3 '25 | 2025-09-30 | $67.45M | $-91.25M | $-0.25 | $-78.70M |
| Q2 '25 | 2025-06-30 | $59.95M | $-111.66M | $-0.33 | $-67.45M |
| Q1 '25 | 2025-03-31 | $49.32M | $-116.16M | $-0.36 | $-103.69M |
| Q4 '24 | 2024-12-31 | $73.69M | $-78.56M | $-0.25 | $-73.30M |
| Q3 '24 | 2024-09-30 | $58.55M | $-83.54M | $-0.28 | $-58.97M |
| Q2 '24 | 2024-06-30 | $31.11M | $-97.10M | $-0.34 | $-98.43M |
| Q1 '24 | 2024-03-31 | $715.00K | $-112.98M | $-0.42 | $-122.28M |
| Q4 '23 | 2023-12-31 | $482.00K | $-116.38M | $-0.45 | $-83.97M |
| Q3 '23 | 2023-09-30 | $469.00K | $-113.76M | $-0.46 | $-84.08M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-06
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
7.67
P/S
17.38
EV/EBITDA
—
EV/Sales
17.04
ROE
-39.3%
ROA
-31.6%
Div Yield
0.00%
FCF Yield
-4.68%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$5.65B
as of 2026-10-19
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
64.83M
SI % of Float
16.70%
Days to Cover
2.83
Short Vol Ratio
38.8%
Free Float
388.15M
Float %
85.7%
Short interest 2026-09-30 • Short volume 2026-10-19 • Float 2026-08-07